ATE237616T1 - Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv - Google Patents

Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv

Info

Publication number
ATE237616T1
ATE237616T1 AT00902768T AT00902768T ATE237616T1 AT E237616 T1 ATE237616 T1 AT E237616T1 AT 00902768 T AT00902768 T AT 00902768T AT 00902768 T AT00902768 T AT 00902768T AT E237616 T1 ATE237616 T1 AT E237616T1
Authority
AT
Austria
Prior art keywords
methanol
amino
cyclopent
hbv
purine
Prior art date
Application number
AT00902768T
Other languages
English (en)
Inventor
Susan Mary Daluge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE237616T1 publication Critical patent/ATE237616T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT00902768T 1999-02-12 2000-02-11 Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv ATE237616T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903091.8A GB9903091D0 (en) 1999-02-12 1999-02-12 Therapeutic nucleoside compound
PCT/GB2000/000429 WO2000047581A1 (en) 1999-02-12 2000-02-11 Therapeutic nucleoside compound

Publications (1)

Publication Number Publication Date
ATE237616T1 true ATE237616T1 (de) 2003-05-15

Family

ID=10847550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00902768T ATE237616T1 (de) 1999-02-12 2000-02-11 Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv

Country Status (15)

Country Link
US (1) US6630477B1 (de)
EP (1) EP1150981B1 (de)
JP (1) JP2002536448A (de)
KR (1) KR20010102081A (de)
CN (1) CN1346356A (de)
AT (1) ATE237616T1 (de)
AU (1) AU2450900A (de)
DE (1) DE60002172T2 (de)
DK (1) DK1150981T3 (de)
ES (1) ES2195861T3 (de)
GB (1) GB9903091D0 (de)
HK (1) HK1039935B (de)
PT (1) PT1150981E (de)
PY (1) PY990158A (de)
WO (1) WO2000047581A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2210373C1 (ru) * 2002-07-03 2003-08-20 Государственное учреждение Тверская государственная медицинская академия Способ лечения тяжелого и затяжного течения острого вирусного гепатита
WO2007148083A2 (en) * 2006-06-21 2007-12-27 Ge Healthcare As Stabilisation of radiopharmaceutical precursors
WO2019099595A1 (en) * 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. NANO-EMULSION OF CBFβ-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2793825B2 (ja) * 1988-01-20 1998-09-03 リージヤンツ・オブ・ザ・ユニバーシテイ・オブ・ミネソタ ジデオキシジデヒドロ炭素環式ヌクレオシド
US4916224A (en) * 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE68907013D1 (de) 1988-10-24 1993-07-15 Wellcome Found Guaninderivate mit antiviraler wirkung und deren pharmazeutisch vertraegliche salze.
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
EP0468119A1 (de) * 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Neue Carbocyclische Analoge einiger Nukleoside
JPH06199812A (ja) * 1991-02-12 1994-07-19 Takeda Chem Ind Ltd 新規シクロペンテン誘導体
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt

Also Published As

Publication number Publication date
JP2002536448A (ja) 2002-10-29
WO2000047581A1 (en) 2000-08-17
DE60002172T2 (de) 2003-11-27
PY990158A (es) 2001-12-03
GB9903091D0 (en) 1999-03-31
HK1039935A1 (en) 2002-05-17
DK1150981T3 (da) 2003-07-21
EP1150981A1 (de) 2001-11-07
AU2450900A (en) 2000-08-29
DE60002172D1 (de) 2003-05-22
KR20010102081A (ko) 2001-11-15
HK1039935B (en) 2003-12-19
US6630477B1 (en) 2003-10-07
ES2195861T3 (es) 2003-12-16
EP1150981B1 (de) 2003-04-16
CN1346356A (zh) 2002-04-24
PT1150981E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
PT1296711E (pt) E7 de vph para o tratamento do virus do papiloma humano
ATE500808T1 (de) Onkolytische virustherapie
SE9702860D0 (sv) New use
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
MD990258A (en) Method of treatment of the acute viral hepatitis B
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
PT888114E (pt) Utilizacao de (+)-alfa-(2,3-dimetoxifenil)-1-¬2-(4-fluorofenil)etil|-4-piperidinometanol no tratamento de doencas depressivas e doencas bipolares
ATE237616T1 (de) Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
NZ512850A (en) Treatment of papillomavirus infections
MY124071A (en) Treatment of viral disease in swine
EP0757697A4 (de) Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
EP1143981A4 (de) Behandlung und vorbeugung von hiv- und anderen virus infektionen
HRP20030701A2 (en) Natural antibodies active against hiv virus
TR199800850T2 (xx) Kan� d�zenleyici bile�imler.
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
UA36485A (uk) Спосіб лікування генералізованого пародонтиту
DE59405845D1 (de) Verwendung von 2-Methylamino-2-phenylcyclohexanon zur Behandlung von Infektionen und zur Immunmodulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1150981

Country of ref document: EP